Brookline analyst Tyler Bussian downgraded Annovis Bio to Hold from Buy with a $9 price target. The analyst cites Phase 3 trial uncertainty for the downgrade after the company modified the primary endpoint. The firm says a significant improvement in MDS-UPDRS II has not been recorded as a primary outcome in a Phase3 Parkinson’s disease trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANVS:
